Search results
Showing 1 to 12 of 12 results for rucaparib
Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.
Evidence-based recommendations on rucaparib (Rubraca) for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
This guideline covers detecting, diagnosing and treating women (aged 18 and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.
Awaiting development Reference number: GID-TA11219 Expected publication date: TBC
Awaiting development Reference number: GID-TA11216 Expected publication date: TBC
Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Awaiting development Reference number: GID-TA11049 Expected publication date: TBC
Discontinued Reference number: GID-TA10168
Awaiting development Reference number: GID-TA11048 Expected publication date: TBC
Discontinued Reference number: GID-TA10492
Discontinued Reference number: GID-TA10490
This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.